Vyloy access in Pakistan
How patients in Pakistan access Vyloy (zolbetuximab-clzb) for first-line CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma through the DRAP Special Permission Personal Use Import pathway.
Ask about Vyloy in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
1. Quick orientation
Vyloy is the first and only FDA-approved CLDN18.2-directed monoclonal antibody therapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive. It is manufactured by Astellas Pharma, was FDA-approved on 18 October 2024 in combination with fluoropyrimidine- and platinum-containing chemotherapy, and was approved earlier the same year in Japan (March 2024), the United Kingdom (August 2024), and the European Union (September 2024). Vyloy is not registered with the Drug Regulatory Authority of Pakistan (DRAP), and Pakistani patients with a confirmed CLDN18.2-positive result on the VENTANA CLDN18 (43-14A) RxDx companion diagnostic (or its locally validated equivalent IHC assay) reach for the medicine through the DRAP Special Permission Personal Use Import pathway. Reserve Meds coordinates the United States sourcing, the cold-chain regulatory documentation, and the international logistics into a Pakistani oncology infusion center, while clinical decisions remain with your treating oncologist.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
2. Why Pakistan patients need Vyloy through the named-patient pathway
For a Pakistani patient with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, Vyloy is the only FDA-approved targeted option, and the alternative is chemotherapy alone. The structural access gap in Pakistan is twofold. Vyloy is not on the DRAP register, and even more practically, the companion diagnostic infrastructure for CLDN18.2 testing is still being built at many Pakistani tertiary oncology services. Patients often arrive at consultation with HER2 status documented but no CLDN18.2 status, and the pathology referral workflow must be set up before a Vyloy case can move.
The DRAP Special Permission Personal Use Import framework is the documented lawful route, and Reserve Meds operates inside that framework as the United States-side coordinator while a PMDC-licensed oncologist at one of these centers holds the clinical relationship.
3. The DRAP Special Permission pathway for Vyloy
DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing Division's Import and Export Section. For unregistered medicines required by a specific patient, DRAP issues a Special Permission, also called the No Objection Certificate (NOC) for Personal Use Import. Applications are filed through DRAP's Online Import and Export System (OIES). For a Vyloy case, the institutional Special Permission for Import of Unregistered Therapeutic Goods filed by the hospital pharmacy is the typical route, since Vyloy is an infused biologic and must be administered at a certified oncology infusion center.
The cell-specific clinical-justification angle for Vyloy is the documented CLDN18.2-positive companion diagnostic result. The application package typically includes the treating oncologist's clinical justification letter setting out the gastric or GEJ adenocarcinoma diagnosis (stage, histology), the confirmed HER2-negative status, the confirmed CLDN18.2-positive status (the VENTANA CLDN18 RxDx assay result, or the locally validated equivalent IHC assay reading 75 percent or greater of tumor cells with moderate-to-strong membranous staining), the planned chemotherapy backbone (mFOLFOX6 per the SPOTLIGHT regimen, or CAPOX per the GLOW regimen), the patient's body surface area (since Vyloy dosing is BSA-weighted), the planned premedication for nausea, vomiting, and infusion reactions, and the projected number of cycles for the initial supply. The PMDC license verification of the treating physician is attached. The patient identifier is the CNIC.
Product details include the brand name (Vyloy), the generic name (zolbetuximab-clzb), the manufacturer (Astellas Pharma US, Inc.), the modality (lyophilized powder for reconstitution, single-dose 100 mg and 300 mg vials), and the cold-chain requirement (storage at 2-8 degrees Celsius in the original carton, protected from light, never frozen). A manufacturer or authorized distributor letter confirms the product is genuine and sourced through the legitimate United States DSCSA-compliant chain. The dispensing facility's institutional license accompanies the package, and the institution must confirm cold-chain receiving capability and oncology infusion center certification. We give you a written timeline estimate for your case before you commit.
4. Where Vyloy gets dispensed in Pakistan
Vyloy dispensing in Pakistan concentrates at the tertiary oncology services with cold-chain receiving infrastructure and certified oncology infusion centers.
The cell-specific institutional filter for Vyloy is twofold: 2-8 degrees Celsius cold-chain receiving capability with continuous temperature monitoring, and the institutional pathology service that can validate CLDN18.2 status. Centers without on-site CLDN18.2 testing typically refer the pathology block to a partner laboratory before the oncology decision is finalized.
5. Real cost picture for Vyloy in Pakistan
Medicine price: quote on request. You get a written quote for your case before you commit.
6. Typical timeline for Vyloy in Pakistan
We give you a written timeline estimate for your case before you commit. Cold-chain biologics add two to three days to the international logistics leg versus an ambient shipment, since the validated 2-8 degrees Celsius shipper requires careful lane planning. Treatment continues until disease progression, unacceptable toxicity, or a physician and patient decision to stop; oxaliplatin within the chemotherapy backbone is typically capped at 6 to 8 cycles before transitioning to fluoropyrimidine plus Vyloy maintenance.
7. What your physician needs to provide
The clinical justification letter, signed by a PMDC-licensed medical oncologist, is the cornerstone of the application. For Vyloy, the letter sets out the gastric or GEJ adenocarcinoma diagnosis (with stage and histology), the confirmed HER2-negative status, the confirmed CLDN18.2-positive status (the VENTANA CLDN18 RxDx report, or the locally validated equivalent IHC assay reading 75 percent or greater of tumor cells with moderate-to-strong membranous staining), the patient's body surface area, the planned chemotherapy backbone with rationale (mFOLFOX6 q2w paired with the SPOTLIGHT regimen, or CAPOX q3w paired with the GLOW regimen), the dosing plan (Vyloy 800 mg per square metre IV on Day 1 of Cycle 1 as loading dose, then 600 mg per square metre IV every 3 weeks on the CAPOX cadence, or 600 mg per square metre on the mFOLFOX6 q3w shifted cadence), and the premedication plan for nausea, vomiting, and infusion reactions. The treating oncologist confirms infusion-reaction readiness at the certified infusion center.
The monitoring plan attached to the application typically describes pre-infusion premedication, standard oncology labs between cycles, attention to gastrointestinal toxicity (particularly during the loading dose), and the chemotherapy-backbone monitoring (CBC, renal function, hepatic function, neuropathy assessment). Adverse events are reported through the DRAP Pharmacovigilance Centre.
8. Common questions about Vyloy in Pakistan
Is CLDN18.2 testing required before Vyloy? Yes. Treatment eligibility depends on a confirmed CLDN18.2-positive result via the VENTANA CLDN18 (43-14A) RxDx companion diagnostic, or a locally validated equivalent IHC assay reading 75 percent or greater of tumor cells with moderate-to-strong membranous staining. Many Pakistani tertiary oncology centers do not yet run this assay routinely; the typical workflow is pathology block referral to a partner laboratory before the oncology decision is finalized.
Does Vyloy treat HER2-positive gastric cancer? No. The FDA-approved indication is restricted to HER2-negative, CLDN18.2-positive disease. HER2-positive gastric cancer follows a separate pathway with different targeted agents.
What is the safety profile? The most common adverse reactions reported in the SPOTLIGHT and GLOW trials were nausea, vomiting, decreased appetite, diarrhea, peripheral sensory neuropathy, fatigue, neutropenia, decreased weight, abdominal pain, and constipation. Infusion-related reactions and gastrointestinal toxicity (particularly during the loading dose) are the safety signals that drive monitoring requirements. The first cycle is the highest-risk infusion.
Will a private insurer cover Vyloy? Coverage for named-patient imports of recently approved targeted biologics is uncommon. Some private health plans cover in-hospital chemotherapy and radiotherapy in their formularies, but Vyloy as an unregistered specialty import is typically outside formulary. Reserve Meds supplies the documentation an insurer needs to assess the claim. The realistic default is cash-pay.
Why this drug versus chemotherapy alone? In SPOTLIGHT (mFOLFOX6 backbone), Vyloy plus mFOLFOX6 produced a 25 percent reduction in the risk of disease progression or death versus placebo plus mFOLFOX6. In GLOW (CAPOX backbone), median progression-free survival was 8.2 months with Vyloy plus CAPOX versus 6.8 months with placebo plus CAPOX, and median overall survival was 14.4 months versus 12.2 months. The decision is made by the treating oncologist on a per-patient basis.
What is the typical course duration? There is no fixed course length. Treatment continues until disease progression, unacceptable toxicity, or a physician and patient decision to stop. Oxaliplatin within the chemotherapy backbone is typically limited to 6 to 8 cycles before transitioning to maintenance.
9. Where Reserve Meds fits in Vyloy cases
Reserve Meds is a US-based digital health company. We do not replace your treating oncologist, we do not replace DRAP, we do not replace your dispensing hospital pharmacy or infusion center. What we do for a Vyloy case is orchestrate the United States-side sourcing exclusively through DSCSA-authorized specialty oncology pharmacies, the regulatory documentation kit for the DRAP institutional Special Permission application, the validated 2-8 degrees Celsius cold-chain logistics through bonded air freight with continuous temperature monitoring, the FBR Customs coordination at the port of entry, and a single point of contact who stays with the case across infusion cycles. Reserve Meds enforces a CLDN18.2 status confirmation before any shipment, to avoid sending product the destination physician cannot prescribe.
Standard NPP coordination applies.
10. Next step
We confirm eligibility within one business day and send the documentation kit to your physician and hospital pharmacy.